AbbVie
ABBV
Performance
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Recent News
AbbVie Tries a New Approach in 340B Programme Battle
Pharma 5.0, Sustainability & Security: PHARMAP 2026 Brings Pharma’s Future Into Focus
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More
Biotech in 2025: A Retrospective
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
In a First, a Drugmaker’s Lawsuit Challenges HRSA’s 340B Patient Definition
Senju Launches First-in-Class Dry Eye Disease Drug in Japan
Analysis Finds Efficiencies, Savings of Using a Single Bispecific for DLBCL and FL
Amgen Adds AML Candidate in Deal for U.K.-based Dark Blue: Deals Report
AbbVie Says Immunology Blockbusters Will Be 'Main Drivers' Of Growth Post-Humira
FDA Revises Recommendation on First Full Epcoritamab Dose in R/R DLBCL to Allow Outpatient Monitoring
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
The Top 10 PharmTech Videos of 2025
Inside NImmune’s Phase 3 Push in Ulcerative Colitis
Proteasomes: A Novel Approach to Target the Immune System
FDA to Meet Novo Nordisk on Troubled Site; AbbVie Buys Drug-Device Factory
CMS's Medicare Price Negotiations Start Round Three
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch
Neomorph Raises $100M for Molecular Glues; Spyre's Ulcerative Colitis Data
Tenpoint Wins FDA Nod for Combination Presbyopia Eye Drop
Report Says MSD Is in Talks to Buy Revolution Meds
SCHD: Your Complete Guide To The March 2026 Index Reconstitution
9 Companies Hiring Now in Pennsylvania
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
AbbVie, AstraZeneca Lose Appeal in Louisiana 340B Contract Pharmacy Fight
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
The FDA Has Released Draft Guidance for NAMs Validation – Now What?
Buffett’s Tax‑Free Self‑Investment Advice Fuels Surge in Dividend‑ETF Picks
11 Companies Hiring Manufacturing Professionals Now
Former FDA Deputies Land at Lilly, AbbVie; Italy's Angelini Has a New CEO
Hiring Outlook: February Brings First YOY Job Increase Since 2022
10 Companies Hiring IT Professionals Now
Boehringer Signs €1bn+ Deal for Simcere IBD Candidate
2025 Novel Large Molecule FDA Drug Approvals
Parkinson’s Awareness Month and World Parkinson’s Day 2026: Advocacy and Therapeutic Progress
Hippocratic AI Builds in Life Sciences with Grove AI Buy
Combination of Ranibizumab, Dexamethasone Superior to Ranibizumab Alone for Macular Edema
IBS Awareness Month 2026: The Hidden Realities of IBS and the IBS Treatment Market
The $500,000 Portfolio To Potentially Pay All Your Bills
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
Johnson & Johnson’s Pipeline Strategy: What Does 2026 Have in Store for the Big Pharma?
AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
The Most Innovative Artificial Intelligence Companies of 2026
The Price Americans Pay for Medicine Has Gotten Horribly Out of Control. Here’s How to Fix It.
JPM26: Galapagos' New CEO Is Here to Finally Turn The Ship Around
Alumis Soars as TYK2 Drug Hits Mark in Psoriasis Trials
